SCIENCE AND RESEARCH

The science behind Testosterone

Evidence-based care for men with testosterone deficiency
2
blood tests
before diagnosis
9,000+
9k+
men in real-world safety cohort
6
TRT papers
published
14,000+
14k+
MEN TREATED

Evidence based care

Testosterone deficiency is a well-documented medical condition that can cause symptoms such as low mood and energy, poor sexual function and reduced muscle mass. For men who have it, TRT is one of the most effective evidence-backed treatments in men's health.
Voy's clinical approach is built on published research, evidence based guidelines, and doctor-led assessment. Every patient is tested, reviewed and monitored. Our aim is simple: to help the right men get the right care, safely and responsibly.
OUR APPROACH

How Voy approaches testosterone deficiency

Diagnosing testosterone deficiency properly takes more than a single blood test.


Our protocol is built from international clinical guidelines to make sure we're identifying the right men — and not treating those who don't need it.
Symptoms
Testosterone replacement therapy (TRT) is only used in those with low testosterone levels and symptoms (such as low mood, low energy, poor sexual function and weight gain). Both are required for a TRT doctor to make the diagnosis of testosterone deficiency and then to consider TRT.
Two tests, not one
A single low result isn't enough. Testosterone levels naturally fluctuate, so we require two separate blood tests before any diagnosis is made. Both must confirm deficiency before treatment is considered.
Test timing
Testosterone levels vary throughout the day. We recommend morning testing for all patients. For men over 40, evidence shows this variation is less pronounced, so tests taken before 2pm are accepted — though morning remains preferred1.
What we measure
We look at two things: total testosterone and free testosterone.

Total testosterone is the overall amount in your blood. We use a threshold of below 15 nmol/L — the level the British Society for Sexual Medicine defines as the lower boundary of normal.

Free testosterone is the testosterone your body can actually use. Some men have adequate total testosterone but most of it is bound to proteins in the blood, making it unavailable. In these cases, free testosterone is the more clinically relevant measurement. We apply a free testosterone threshold guided by the International Consultation for Sexual Medicine.
Screening before treatment
Before any treatment is considered, we screen for conditions that can mimic low testosterone and check that TRT would be safe to start. Nobody should be started on testosterone without this step.

How common is 
testosterone deficiency?

Some research suggests as many as 25% of men have low testosterone blood levels2. But low levels alone don't tell the whole story.
Many men with low testosterone never develop symptoms, and may never need treatment. This is why we only treat men who have both low testosterone levels and symptoms. When the two are present together, this is called testosterone deficiency — or its medical name, hypogonadism. It can result from a problem with the testicles, or more commonly from the hormone system gradually becoming less efficient over time.
It’s unknown how many men with low testosterone also have symptoms, but the research suggests somewhere between 6-30%3.
This is why blood tests alone are never enough. Symptoms matter, and every patient at VOY is assessed by a doctor before any treatment is considered.
SAFETY EVIDENCE

Understanding
the risks of TRT

TRT is a well-studied and generally safe treatment for testosterone deficiency. 



But like any medical treatment, it carries risks that every patient should understand before starting. Our medical service is designed to identify, discuss and monitor these risk throughout your care.
Fertility
Some TRT regimens can suppress natural sperm production. If preserving fertility matters to you, this will be part of your conversation with your doctor before starting. Treatment options to support fertility alongside TRT are available, and your doctor will discuss these based on your circumstances.
Testicular function
TRT can reduce the testes' natural activity. This typically reverses if treatment is stopped, although prolonged use can occasionally lead to some testicular shrinkage or a reduction in natural testosterone production. Although this may not be a concern for everyone, there are standard treatment additions that can mitigate against these side effects and your doctor will discuss what's right for you.
Blood thickness
TRT stimulates red blood cell production, which can benefit energy and physical performance. However, in some men the body can react too well and produce too many red blood cells which can thicken the blood and raise the risk of clots. We monitor this carefully with blood tests at 3 months, 6 months, and every 6 months thereafter. We also have robust preventative pathways in place for those who are at risk.
Heart health
TRT can be unsafe in certain heart conditions such as severe heart failure, but generally research has shown it to be safe for the heart, including in men who have previously had a heart attack as demonstrated in the landmark TRAVERSE trial⁴ and more recently in this large review of all the evidence.
Prostate health
TRT does not cause prostate cancer. However, if prostate cancer is already present, TRT can accelerate it. We screen for this before treatment begins and continue to check at every monitoring blood test throughout your care.
PUBLICATIONS

TRT Research

Our approach combines original research with insights from the broader scientific community. We conduct and publish our own studies in established, peer-reviewed journals, while also drawing on the latest independent research to ensure our recommendations reflect the strongest available evidence.

Our latest findings

Curious about our research? Browse our publications and conference highlights.

paper
TRT
·
MAY 2025

What UK Men Who Use TRT Really Think About the Treatment

paper
TRT
·
MAY 2025

A Qualitative Exploration of Testosterone Replacement Therapy.

paper
Weight loss
·
July 2025

What People in the UK Really Think About GLP-1 Medications for Weight Loss

paper
Weight loss
·
March 2025

Using Digital Programs to Support Weight Loss on GLP-1 Medications Treatment, 5 month analysis

paper
Weight loss
·
October 2025

Safe, Effective, Supported: 11-Month Results from Voy's Digital GLP-1 Weight Loss Programme

paper
Hair loss
·
July 2025

Combined Oral Minoxidil and Finasteride for Male
Hair Loss: Real-World Results

paper
TRT
·
July 2025

What Men in the UK Really Know About Testosterone Deficiency

paper
TRT
·
July 2025

How Testosterone Treatment Affects Cardiovascular Health and Blood Markers

paper
TRT
·
2025

Real-World Outcomes and Safety of Testosterone Therapy

paper
Weight loss
·
November 2025

Engaging with Voy's Digital Programme Helps People on Mounjaro Lose More Weight: 12-Month Study Results

Caret
Caret

Publications we're proud to feature in

Our research has been published in established, peer-reviewed journals, reflecting independent review and rigorous academic standard.

AJMH
Women's Health
BJD
BMJO
JMIR
DOM_Journal
JSM
JCO
European Congress of Obesity
The Independent
WJMH_Logo
TUMH
TAU
The Menopause Society
Obesity Week
JCEM
Endo2025
BMJPH
Cureus
IJIR
European-Society-of-Endocrinology

Voy’s science and research experts

Our university partners

We partner with globally renowned universities to provide independent academic input, methodological rigour and peer-review expertise.

Dr Ranjith Ramasamy
TRT
Dr Ranjith Ramasamy
Cornell-trained urologist and researcher known for academic contributions to advancing care in male infertility and testosterone deficiency
Dr Austen El-Osta
Weight loss
Dr Austen El-Osta
Director of SCARU at Imperial College London, leading global research on self-care, digital health, inclusion, and wellbeing.
Dr Fatima Stanford
Weight loss
Dr Fatima Stanford
Obesity medicine physician scientist, educator, and policy maker at Massachusetts General Hospital and Harvard Medical School.
Dr Mo Khera
TRT
Dr Mo Khera
Professor of Urology at Baylor College of Medicine, specialising in sexual dysfunction, men’s health, and hormone replacement therapy.
Prof Giles Yeo MBE
Weight loss
Prof Giles Yeo MBE
Professor of Molecular Neuroendocrinology at the MRC Metabolic Diseases Unit, University of Cambridge.
Dr Ranjith Ramasamy
TRT
Dr Ranjith Ramasamy
Cornell-trained urologist and researcher known for academic contributions to advancing care in male infertility and testosterone deficiency
Dr Austen El-Osta
Weight loss
Dr Austen El-Osta
Director of SCARU at Imperial College London, leading global research on self-care, digital health, inclusion, and wellbeing.
Dr Fatima Stanford
Weight loss
Dr Fatima Stanford
Obesity medicine physician scientist, educator, and policy maker at Massachusetts General Hospital and Harvard Medical School.
Dr Mo Khera
TRT
Dr Mo Khera
Professor of Urology at Baylor College of Medicine, specialising in sexual dysfunction, men’s health, and hormone replacement therapy.
Prof Giles Yeo MBE
Weight loss
Prof Giles Yeo MBE
Professor of Molecular Neuroendocrinology at the MRC Metabolic Diseases Unit, University of Cambridge.

Internal Experts

Our research is guided by experienced medical advisors who provide independent clinical oversight, helping to ensure our work meets high standards and clinical relevance.

Operations
Rana Mirzai
Lead TRT clinician
David Huang
Leadership
David Huang
Doctor with over 10 years experience building health technologies in the NHS and privately. Responsible for medical affairs, clinical research and partnerships.
Jeff Foster
Men’s Health
Jeff Foster
NHS GP Partner and men's health specialist, guideline author on testosterone deficiency, BSSM committee member.
Earim Chaudry
Leadership
Earim Chaudry
NHS GP Partner and founding member of Voy, with over 20 years of experience in healthcare across Europe’s most innovative digital and AI health organisations.
Men’s Health
Anand Patel
Expert in men’s health and sexual medicine, BSSM commitee member, GP partner with over 25 years of healthcare experience

Research collaborators

Our research is guided by experienced medical advisors who provide independent clinical oversight, helping to ensure our work meets high standards and clinical relevance. We also collaborate with university and co-researcher teams on long-term scientific projects, leveraging their expertise to advance our research and drive healthcare innovation.

Genetics and Hormones
Prof Ken Ong

Professor of Paediatric Endocrinology researching early-life determinants of obesity, diabetes, and metabolic disease risk.

Genetics and Hormones
Prof John Perry

Professor of Molecular Endocrinology researching genetic and biological pathways linking early growth to cardiometabolic health.

TRT
Dr Abe Morgentaler

Associate Professor of Urology and pioneer of modern testosterone therapy and men’s hormonal health.

Precision Medicine
Dr Ben Reis

Director of Predictive Medicine, developing data-driven systems to predict disease and improve population health.

Citations
1 Welliver, R Charles Jr et al. “Validity of midday total testosterone levels in older men with erectile dysfunction.” The Journal of urology vol. 192,1 (2014): 165-9. doi:10.1016/j.juro.2014.01.085
2 Araujo, Andre B et al. “Prevalence of symptomatic androgen deficiency in men.” The Journal of clinical endocrinology and metabolism vol. 92,11 (2007): 4241-7. doi:10.1210/jc.2007-1245
3 Allan, Carolyn A, and Robert I McLachlan. “Age-related changes in testosterone and the role of replacement therapy in older men.” Clinical endocrinology vol. 60,6 (2004): 653-70. doi:10.1111/j.1365-2265.2004.02002.x
4 Hackett, Geoffrey Ian. “Long Term Cardiovascular Safety of Testosterone Therapy: A Review of the TRAVERSE Study.” The world journal of men's health vol. 43,2 (2025): 282-290. doi:10.5534/wjmh.240081
5 García-Becerra, Carlos A et al. “Cardiovascular and prostate cancer risk associated to testosterone replacement therapy - a systematic review and meta-analysis of 41 randomized controlled trials.” International journal of impotence research, 10.1038/s41443-026-01237-4. 11 Feb. 2026, doi:10.1038/s41443-026-01237-4

Making healthy living a joyful normality

Because thriving, now, and in later life can and should be the norm for everyone.

Explore our treatment areas